Kornimate/medical-research-clean huggingface dataset:
laparoscopic lens defogging using anti-fog solution, warm saline, and chlorhexidine solution

Conditions: Gynecologic Disease

Summary: the aim of this study is to compare three popular methods of minimizing or reducing laparoscopic lens fogging (llf) by heating lens using warm saline, applying anti-fog agent to lens, and rubbing lens with chlorhexidine in laparoscopic gynecologic surgery.

the physiology behind laparoscopic lens fogging (llf) is well understood based on meticulous experiments outlining the role of temperature and humidity. despite many efforts, including uses of warm saline, various anti-fog agents, chlorhexidine, betadine, and rubbing the lens on serosal surfaces, to reduce llf, there remains no consensus as to which method is superior to prevent llf. furthermore, most previous studies were experimental trials conducted in a simulation model or a non-human in vivo model or an expert's commentary based on their clinical experiences , and there was no randomized controlled trial focusing llf in human model. therefore, this randomized trial aimed to compare three popular methods of minimizing or reducing llf by heating lens using warm saline, applying anti-fog agent to lens, and rubbing lens with chlorhexidine in laparoscopic gynecologic surgery.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * american society of anesthesiologists physical status (asaps) classification i-ii * the absence of pregnancy at the time of surgery exclusion criteria: * allergy to chlorhexidine or anti-fog solution * anticipating cases of abrupt change in intra-abdominal humidity such as hemoperitoneum and profuse ascites * extremely short or long operative time (\ 180 min) affecting the frequency of llf * unavailability of the surgical recording equipment for laparoscopic procedure.
noninvasive cardiac output measurements in patients with pulmonary hypertension undergoing right heart catheterization with acute vasodilator testing

Conditions: Pulmonary Hypertension

Summary: subjects in this study have been diagnosed with pulmonary hypertension (ph) and their doctors have referred them for a right heart catheterization (rhc). heart catheterization involves inserting an iv (a needle with a small tube) into a vein in the neck. a long, narrow tube, called a catheter, is guided through the iv into the blood vessel and guided to the heart (sometimes this procedure can be done through a vein in the groin instead). once the catheter is in place, small instruments can be inserted into the catheter to measure the pressures in different areas of the heart. these measurements can help the doctor diagnose possible problems with the heart functioning. the purpose of this study is to evaluate the measurements provided by a device, called noninvasive cardiac output monitoring (nicom). the nicom device is non-invasive which means the investigators do not have to go inside the body to obtain the heart pressure measurements. while the device has been approved for use in any patient, it remains possible that patients with ph will have differences in the way the device calculates measurements. in this study, the investigators will compare the in-the-body (right heart catheterization) measurements to the non-invasive, outside-body measurements provided by the nicom device to evaluate any differences. the nicom device is approved by the us food and drug administration (fda) to measure heart pressures. this device is usually used when a patient can't undergo a right heart catheterization. in this study, the investigators are using the device to gather heart pressure measurements for research during the right heart catheterization procedure that is scheduled as part of the patients' normal, routine care. the research data is being used to devise better, less invasive ways to assess disease severity, track disease progression and evaluate response to therapy. the nicom device is made by cheetah medical.


Eligibility criteria:
inclusion criteria: * 18 years old and up * have pulmonary hypertension (ph) * scheduled for cardiac catheterization with right heart catheterization and acute vasodilator testing as part of their evaluation of ph exclusion criteria: * unable or unwilling to give informed consent

Keywords: cardiac pulmonary hypertension to determine the accuracy of a noninvasive method of measuring cardiac output as compared to the standard invasive approach in patients with ph
preference study with elderly patients recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

approximately 60% of all cancer diseases appear to people aged 65 years and older. ovarian cancer is the most frequent cause of death among gynaecological malignant tumours. since the highest carcinoma incidence is between the 60th and 70th year more women will come down with ovarian cancer because of increased life expectancy. at least 65% of patients with figo stage iii/iv will exhibit a relapse or progress after first-line therapy. in most studies the age of the patients is limited to 65 years. it could be shown that especially elder patients often receive an inadequate operative and cytostatic therapy resulting in a worse prognosis. patients aged 70 years or elder who will be treated with treosulfan, given oral or intravenous, shall be compared regarding the patient compliance, toxicity especially hematological and gastrointestinal toxicity grade 3-4 (ctc nci), overall survival, progression free survival, quality of life.

Eligibility criteria:
inclusion criteria: * patient with relapsed ovarian cancer * study therapy of third regime * measurable or evaluable tumor lesions or progression defined as ca-125 more than \>= 100 u/ ml. * age \>= 70 years * ecog 0-2 * written informed consent exclusion criteria: * pretreatment with treosulfan * patient without measurable or evaluable tumor lesions or ca-125 more than \>= 100 u/ ml. * no adequate bone marrow function (leukocyte \<= 2,9 x 109/l, platelets \<= 100 x 109/ l * creatinin and bilirubin within \>= 1,25 x fold of the reference laboratory´s normal range * simultaneous radiotherapy
anesthesia modality and oncologic outcomes in high-risk nmibc: a randomized trial

Conditions: NMIBC; TURBT; Bladder (Urothelial, Transitional Cell) Cancer; Bladder Cancer Recurrence; Anesthesia, General; Anesthesia,Spinal

Summary: to demonstrate the superior efficacy of spinal anesthesia (sa) versus general anesthesia (ga) according to the delay of time to recurrence in high-risk nmibc patients up to week 104 after turbt.


Eligibility criteria:
inclusion criteria: * age ≥40 years for male subjects or postmenopausal female subjects * ecog performance status 0-2 * patients with suspected or newly diagnosed ubuc * asa i or ii * patients with any other adequately treated stage i or ii cancer except uc, from which the subject has been disease free for 5 years * adequate renal function, defined as a serum creatinine (cre) concentration ≤ the institutional uln * adequate hepatic function, defined as total bilirubin ≤ the institutional uln and alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ the institutional upper limit of normal (uln) exclusion criteria: * patients with prior or concurrent uc involving the renal pelvis, ureter or urethra * patients with clinical evidence of mibc or muc * immunocompromised or immunosuppressed patients * patients with chronic use of anti-inflammatory agents or beta-blockers * patients with difficult airways or other significant cardiovascular comorbidities (severe aortic stenosis, significant pulmonary disease, chf) who are intolerant to ga * patients with elevated intracranial pressure (icp), primarily due to intracranial mass and trauma or infection at the site of sa * patients with a serious uncontrolled medical disorder (e.g., trauma, fracture) or active infection that would impair their ability to receive spinal or ga * patients with known allergies to propofol, fentanyl, sevoflurane, or bupivacaine * subjects with a known history or family history of malignant hyperthermia * subjects with bleeding diathesis

Keywords: bladder cancer general anesthesia spinal anesthesia recurrence turbt
mesh type in ventral hernia repair

Conditions: Ventral Hernia

Summary: ventral hernias are common following abdominal surgery. currently, there is no equipoise on when synthetic and biologic meshes should be used. among open ventral hernia repairs, half are repaired using biologic mesh while half are repaired using synthetic mesh. the investigators hypothesize that biologic mesh as opposed to synthetic mesh repair of open ventral hernia repair is associated with decreased risk of major complications one year after surgery.


Eligibility criteria:
inclusion criteria: * patient scheduled for open ventral hernia repair at lbj general hospital exclusion criteria: * active infection * patient unlikely to survive with the next 2 years based upon surgeon judgment (i.e. metastatic cancer, end-stage cirrhosis) * patient surgeon would not normally place a prosthetic (e.g. planned second surgery such as ostomy takedown) * patient unlikely to follow-up (i.e. no phone)

Keywords: ventral hernia mesh
cephalic version by acupuncture-moxibustion for breech presentation

Conditions: Breech Presentation

Summary: for breech presentation, the cesarean section rate is decreased by external cephalic version. this is a painful operation, with some rare but serious complications. the aim of this trial is to evaluate the effectiveness of acupuncture-moxibustion, a non-invasive technique, to correct breech presentation before 37 weeks of gestation.

monocentric controlled randomized trial in a simple blind fashion, comparing acupuncture-moxibustion versus a placebo in singleton pregnancies with breech presentation between 33+5 to 35+5 weeks of gestation. the intervention arm consists of acupuncture-moxibustion at the bl67 acupuncture point, for six seances of twenty minutes two days apart. in the placebo group, the cold light of an inactivated laser is to be applied in the same point during the same time. when cephalic version fail, a manual external cephalic version is to be proposed. the main outcome measure is cephalic presentation at 37+2 weeks of gestation.

Eligibility criteria:
inclusion criteria: * breech presentation, * singleton exclusion criteria: * maternal age between 18 ans 45, * multiple gestation, * fetal or uterine malformation, * premature rupture of membranes

Keywords: pregnancy breech acupuncture moxibustion version
diabetes risk communication tool evaluation

Conditions: Type 2 Diabetes

Summary: prevention for type 2 diabetes (t2d)has been vast but with limited success. while singaporeans have high knowledge about t2d, its symptoms, and risk factors, healthy practices are still sub-optimal. upon a qualitative investigation, it was found that there is little to no urgency to engage in t2d preventative behaviour due to to the low perceived threat, and high costs from required lifestyle changes relative to the benefits. hence, this project targets to communicate the risk of diabetes in a more salient and effective way to improve the intention of preventative behaviour by targeting the constructs of protection motivation theory (pmt) and increasing the threat and coping appraisals. the current available diabetes risk assessment tool's result page provides a binary output: "higher vs lower" risk of being pre-diabetic. this aligns with the usual care practiced in clinics currently; patients are told if they are pre-diabetic or not. it does not provide any personalized or relevant tips on how to reduce risk. hence, there was a demonstrated need to develop risk assessment tools that increase threat appraisal and communicate t2d risk in a more salient way to motivate the intention of behaviour change. the investigators developed two tools: relative risk, and metabolic age. the relative risk prototype demonstrates the user's relative risk on a scale of 1 to 10, in comparison to someone of the same age and sex. the number 1-10 represents their position in the percentile distribution of their risk scores. the metabolic age is identified by matching the risk score's percentile position to percentile of the incidence of t2d. the median age of the people in that percentile is reflected as the metabolic age. the primary objectives of this study is to evaluate which of these risk presentations (usual care, relative risk, or metabolic age) evoke (i) effective cognitive and emotional responses to risk results and (2) motivation for the intention of behaviour change. the secondary objective is to provide empirical evidence for using pmt constructs in intervention development. the hypothesis is that those who are exposed to the metabolic age risk assessment and communication tool will have the most effective cognitive and emotional response, and the highest intention of engaging in behaviour change, followed by those exposed to relative risk, and then standard of care.


Eligibility criteria:
inclusion criteria: * aged 30-60 years; * singapore citizen, or permanent resident * able to read and understand english, * have had a health screening with blood pressure, triglycerides, and hba1c done within the last 3 months * at least one risk factor for type 2 diabetes (bmi ≥ 23 kg/m2, blood pressure ≥130/85 mmhg or receiving therapy for hypertension, triglycerides ≥1.7mmol/l or hba1c ≥5.7%) exclusion criteria: - diagnosis of any event of cardiovascular disease, kidney issues, or type 2 diabetes
a study to investigate tislelizumab (bgb-a317) versus placebo in combination with concurrent chemoradiotherapy in participants with localized esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Summary: this is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of bgb-a317 versus placebo with chemoradiotherapy in participants with localized esophageal squamous cell carcinoma.


Eligibility criteria:
key inclusion criteria: * 18 to 75 years on the day of signing the informed consent form * histologically confirmed diagnosis of localized escc * measurable and/or non-measurable disease defined per recist v1.1 * eastern cooperative oncology group (ecog) performance status ≤ 1 * adequate organ function key exclusion criteria: * indicators of severe malnutrition * clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention within 2 weeks prior to randomization * known to be intolerable or resistant to treatment with the protocol-specified chemotherapy * received prior radiotherapy or therapies targeting pd-1, pd-l1, pd-l2 or other immune-oncology therapies * active autoimmune diseases or history of autoimmune diseases that may relapse note: other protocol defined inclusion/exclusion criteria may apply.
ctnna1 familial expansion study

Conditions: Cancer Gene Mutation; Gastric Cancer; Breast Cancer

Summary: the goal of the café study is to determine the cancer risks associated with germline ctnna1 loss-of-function variants.

the café study aims to determine the degree to which loss-of-function variants in the ctnna1 gene are associated with hereditary cancers, including gastric cancer, breast cancer, as well as other cancers that may be associated with this gene. by obtaining personal and family history information from individuals who carry a ctnna1 loss-of-function variant and their family members, this study will aim to better define ctnna1 associated cancer risks and determine whether there is a genotype/phenotype correlation for ctnna1 loss-of-function variants. this information will be important for the future cancer risk management of individuals who carry a ctnna1 loss-of-function variant.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * participants must be carrier, or a first degree relative of a carrier, of a ctnna1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a consensus splice site variant predicted to disrupt splicing in ctnna1. ctnna1 loss-of-function variants do not need to be classified as pathogenic or likely pathogenic to be included. * participants must be able to understand and read english * participants must be able to provide informed verbal or written consent exclusion criteria: * less than 18 years of age * individuals who do not carry a ctnna1 loss-of-function variant and are not a first degree relative of a ctnna1 loss-of-function variant carrier. * individuals who cannot speak and read english * major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation * unable to comply with the study procedures as determined by the study investigators or study staff

Keywords: ctnna1 hereditary diffuse gastric cancer gastric cancer breast cancer
the effect of non-invasive ventilation on the oxygenation of peripheral muscle in hypercapnic copd patients

Conditions: COPD; Hypercapnia

Summary: in this study, 20 hypercapnic copd patients will perform two constant workrate endurance cycle tests. one test will be while using non-invasive ventilation (niv) support, one without in a randomized cross-over design. the aim is to measure, whether niv is able to change peripheral and respiratory muscle oxygenation.

in this study patients will perform one incremental work rate test to obtain peak work rate. on the following days two constant work rate cycle endurance tests (cwrt) will be performed at 60% of peak work rate using a randomised cross-over design. between the two cwrts there will be one hour of recovery time in between. one of the cwrts will be performed with the support of non-invasive ventilation (niv), the other one without. respiratory and cardiovascular parameters will be observed through transcutaneous measurement of co2 (sentec device) and near-infrared spectroscopy devices. the purpose of this study is, to examine whether the use of niv not only decreases patients dyspnoea, but also has positive effects on the patients cardiovascular system, exercise capacity and muscle oxygenation. the investigators will examine the tissue oxygen saturation in the 7th intercostal space (reflecting a respiratory muscle) and on the m. vastus lateralis of the leg during both cwrts. with the support of niv, it is expected to see a change in the oxygenation towards a better perfusion of the leg muscle, due to a facilitation of the work of breathing. this may result in a later onset of leg fatigue and an increased exercise capacity of the patients. to have an equivalent workload all parameters will be compared during isotime. to conclude, aim of this study is to record the interplay of oxygenation and perfusion between the intercostal muscles and the peripheral leg muscle during exercise. the investigators hypothesize, that the use of niv may change the oxygenation in favour of the leg muscle through relieving the respiratory muscles.

Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease gold (global initiative for chronic obstructive lung disease) stage iv * hypercapnia: pco2\>50mmhg (at rest or in exercise) * written consent exclusion criteria: * orthopaedic comorbidities that do not allow a cycle endurance test * acute exacerbation of copd * cardiac insufficiency, acute coronary syndrome

Keywords: copd nirs niv exercise
conduction system pacing optimized therapy

Conditions: Heart Failure

Summary: the purpose of the cspot study is to determine the best mode of cardiac resynchronization therapy (crt) pacing for different populations of crt patients, comparing traditional biventricular or left ventricular pacing (biv), conduction system pacing (csp)-only, and conduction system pacing optimized therapy (cspot) also known as a combination of conduction system pacing (csp) and left ventricular (lv) pacing. additionally, safety of the system will be assessed.


Eligibility criteria:
inclusion criteria: * patient is willing and able to provide written informed consent * subject is at least 18 years of age * patient is willing and able to comply with the protocol, including follow-up visits * the patient's medical records must be accessible by the enrolling site over the follow-up period * standard crt-d or crt-p indications, with a preference for ivcd and non-lbbb patients, where lbbb is defined according to strauss criteria. * de-novo crt implant, including upgrade from pacemaker or icd exclusion criteria: * subject has persistent or permanent af (atrial fibrillation)/afl (atrial flutter) * subject has 2nd or 3rd degree av (atrioventricular) block * subject has rbbb with no additional conduction block * subject has intrinsic (non-paced) qrs width less than or equal to 120 ms * subject experienced mi within 40 days prior to enrollment * subject underwent valve surgery, within 90 days prior to enrollment * subject is post heart transplantation or is actively listed on the transplantation list * subject is implanted with a lv assist device * subject has severe renal disease * subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure * subject has severe aortic stenosis (with a valve area of \<1.0 cm or significant valve disease expected to be operated within study period) * subject has severe aortic calcification or severe peripheral arterial disease * subject has complex and uncorrected congenital heart disease * subject has mechanical heart valve * pregnant or breastfeeding woman (pregnancy test required for woman of child-bearing potential and who are not on a reliable form of birth regulation method or abstinence) * subject is enrolled in another study that could confound the results of this study without documented pre-approval from medtronic study manager
tegaderm vs. transpore for eye protection during anesthesia

Conditions: Eyelid Erythema

Summary: the purpose of this study is to compare the rate of eyelid erythema after anesthesia with the use of tegadermtm vs. the transpore®. our null hypothesis is that the rate of erythema will be similar between the two groups given there is no evidence currently to suggest otherwise

at tufts medical center, a variety of adhesive tapes are used to shut the eyes during anesthesia, including 3mtm tegadermtm and the sharn anesthesia transpore®, with no preference for one or the other. while all of these products decrease the risk of corneal abrasion, none of these products have been shown to be superior to the others in terms of eyelid irritation. according to sharn anesthesia, "the \[transpore®\] adhesive is light enough to reduce damage to the outer eye" (3). however, there is no scientific evidence to support this claim. all the investigators know is that the transpore is coated with a medical grade, pressure-sensitive acrylic adhesive and that there are no phthalates, it is latex free and silicone free.

Eligibility criteria:
inclusion criteria: * at least 18 years old * surgeries scheduled for anesthesia of any duration exclusion criteria: * any patient that does not consent * any patient who has: * pre-existing eyelid erythema or other eyelid trauma * eyelid piercings * any surgery on the head, brain, neck, teeth, mouth, eyes, or face * surgery in the prone position * patients less than 18 years old